concentrato per soluzione per infusione
Sponsors
Bristol-Myers Squibb International Corporation, Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l., Daehwa Pharmaceutical Co. Ltd., Fondazione Ricerca Traslazionale, Istituto Di Ricerche Farmacologiche Mario Negri
Conditions
Early Stage Non-Small Cell Lung Cancer (NSCLC)Extensive-Stage Small-Cell Lung Cancer (ES SCLC)HER2-negativeRecurrent or Metastatic HER2 Negative Breast Cancerbreast carcinomaestrogen receptor–positiveneoadjuvant chemotherapystage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)
Phase 2
Phase 2 trial of Translational approach to first line cHemoimmunotherapy followed by maintenance with pembrOlizumab and olaparib in Extensive-Stage Small-Cell Lung CanceR (THOR trial)
RecruitingCTIS2024-514666-39-00
Start: 2023-03-16Target: 60Updated: 2025-06-11
A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Oral Paclitaxel (DHP107) Compared to IV Paclitaxel as First-line Therapy in Patients with Recurrent or Metastatic HER2 Negative Breast Cancer
Active, not recruitingCTIS2024-517090-24-00
Start: 2020-10-09Target: 10Updated: 2026-01-13
Neoadjuvant chemo-immunotherapy for stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)
RecruitingCTIS2024-519205-35-01
Start: 2025-07-08Target: 30Updated: 2025-09-10
A Pragmatic Phase II Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2− Early Breast Cancer Using Oncotype DX and Abemaciclib - VIOLET trial
Not yet recruitingCTIS2026-525457-37-00
Target: 150Updated: 2026-10-16